Navigation Links
Large-Scale Global Registry to Examine Treatment Patterns and Disease Burden Among Patients with Venous Thromboembolism (VTE)
Date:9/3/2013

AMSTERDAM, Sept. 3, 2013 /PRNewswire/ -- The Thrombosis Research Institute (TRI) today announced the launch of the GARFIELD (Global Anticoagulant Registry in the FIELD) VTE Registry, an innovative research initiative exploring acute and long-term management and outcomes in patients with symptomatic venous thromboembolism (VTE).  Led by an international steering committee under the auspices of the TRI, the registry will follow 10,000 patients with acute VTE in a real-world setting.  GARFIELD VTE is supported by an unrestricted research grant from Bayer HealthCare.

VTE is a disease process that encompasses two interrelated conditions: deep vein thrombosis (DVT), in which a blood clot forms in a deep vein such as the legs, and pulmonary embolism (PE), a life-threatening condition in which part of the clot breaks off and is carried to the lungs through the heart, cutting off the flow of blood to the lungs.  In the Western world, one person dies every 37 seconds from VTE.

"Venous thromboembolism continues to represent an important clinical challenge, with a heavy burden for patients and healthcare systems," said Professor The Lord Kakkar, Professor of Surgery at University College London and Director of the Thrombosis Research Institute, London, UK. "Better understanding how best patient outcomes can be achieved will be greatly assisted through robust outcomes research.  We are grateful for the unrestricted grant from Bayer Healthcare to support the Garfield VTE Registry which builds on our experience in better understanding the real world challenges of providing anticoagulation to prevent thromboembolic stroke in the Garfield AF Registry."

About GARFIELD
GARFIELD is a pioneering outcomes research initiative led under the auspices of the TRI through an unrestricted research grant from Bayer HealthCare.  It is comprised of two large-scale registries: '/>"/>

SOURCE Thrombosis Research Institute
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Large-Scale Kaiser Permanente Program Linked to Improved Blood Pressure Control
2. First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams
3. First Large-Scale Population-Based Study in the U.S. Shows Hologics 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection
4. Large-Scale Meta-Analysis Shows Age Not a Social Barrier to Opioid Use and Misuse
5. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
6. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
7. PharmAthene to Present at Rodman & Renshaw Annual Global Investment Conference
8. Peripheral Vascular Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
9. Philips launches new EPIQ premium ultrasound system with first-of-its-kind nSIGHT technology and Anatomical Intelligence, to address complicated imaging needs of an aging global population
10. MEMS in Medical Applications Market is Expected to Reach USD 6.5 Billion Globally in 2019: Transparency Market Research
11. Injectable Dose Formulations Highly Impact Global Pharmaceutical Contract Manufacturing Vendor Revenues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger than an ... patients to self-inject prescription drugs in the large doses required ... diseases, autoimmune deficiencies, and genetic disorders.  An ... by 2018, according to analysts.   Many of these drugs will ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... New data show the,investigational drug tetrabenazine maintained ... up to 80 weeks in those,patients who ... data suggest that tetrabenazine can be used ... use., "These findings demonstrate the potential benefit ...
... Pharmaceuticals plc,(LSE: CEN), the Cambridge based biopharmaceutical company, ... respected scientific,journal 'Synapse'* on its Phase II NMDA ... a potential treatment for neuropathic,pain. The independent study ... with CNS 5161. , In the study reported ...
Cached Medicine Technology:Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 2Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 3Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3
(Date:4/22/2014)... percent of all lung cancers are small cell ... develop resistance to chemotherapy. However, researchers at Virginia ... insights into the mechanisms leading to this resistance ... Chemotherapies work primarily by mediating B-cell lymphoma 2 ... cell death. Depending on their function, this family ...
(Date:4/22/2014)... have found a way to block abnormal cholesterol production, ... the main cause of heart attacks and strokes and ... develops when fat builds inside blood vessels over time ... their ability to feed oxygen-rich blood to the heart ... experiments, described April 7 in the journal Circulation ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
(Date:4/22/2014)... nanodot technology, Berkeley Lab researchers have demonstrated the ... used to study the membranes of living cells. ... structures can reveal information critical to whether a ... cancerous, that can,t be obtained through conventional microscopy. ... provide a physical means to both probe and ...
(Date:4/22/2014)... (trade name: NovoEight) has been approved since November 2013 ... with haemophilia A. In an early benefit assessment pursuant ... for Medicinal Products" (AMNOG), the German Institute for Quality ... new active ingredient offers an added benefit over the ... an added benefit of turoctocog alfa is not proven. ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3
... and SANTA CLARA, Calif., Jan. 13 Gulf ... care facilities in,the nation, announced it will be ... ultrasound platforms from Eklin Medical Systems.,GCVS currently uses ... and Communications System) as part of the,facility,s Eklin ...
... respiratory distress, researchers say; company says product is safe ... cold remedy Vicks VapoRub may cause airway inflammation that ... study says. , Doctors at Wake Forest University started ... developed severe respiratory distress after the salve had been ...
... Interventions Incorporated into, First-of-its-Kind Study ... Jan. 13 /PRNewswire/ - MEMOTEXT announced today that ... will conduct a clinical trial on patient adherence ... technology developed by MEMOTEXT. The clinical trial, titled ...
... KENNEBUNK, Maine, Jan. 13 The new year brings ... its steadfast commitment to community programs. This month, the ... brings everyday Americans and local communities together with Tom,s ... care for families in need. Over the past four ...
... new turn. Now you can see the ... Early on Christmas morning, CNN ... "What is Telemedicine?" demonstrating how telemedicine is ... healthcare to patients at six area Walmart ...
... Synergy Connect(TM) links health plan, physicians and ... Fla., Jan. 13 Health Integrated, a ... helping people with chronic illnesses get the ... communities. Health Integrated,s groundbreaking Synergy Connect(TM) service ...
Cached Medicine News:Health News:Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions 2Health News:Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions 3Health News:Vicks VapoRub Linked to Infant Breathing Problems 2Health News:Vicks VapoRub Linked to Infant Breathing Problems 3Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 2Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 3Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 4Health News:Tom's of Maine Invites Everyone to Start the New Year by Helping Families in Need 2Health News:Houston's NuPhysicia LLC has Remote Medical Technologies and Services Featured on CNN Health Report 2Health News:Houston's NuPhysicia LLC has Remote Medical Technologies and Services Featured on CNN Health Report 3Health News:Health Integrated Unifies Care Community to Improve Physical, Psychological and Social Health of the Chronically Ill 2Health News:Health Integrated Unifies Care Community to Improve Physical, Psychological and Social Health of the Chronically Ill 3
Medpor 2/3 Orbit implants are designed to replace non load bearing bony structures in the orbital area....
... Implants provide the surgeon with ... of the inferior and lateral ... secondary rim repair. The extended ... and extends around the lateral ...
... Round handle. Divides nucleus for phacoemulsification. Nuclear ... any hardness can be pre-chopped with pre-chop ... nuclear fragments is rapid. Risk of rupturing ... ultra sound time and minimal movement of ...
Phaco chopper 1 mm fully cutting edge....
Medicine Products: